Amcor plc AMCR
Composite 56/100; the shares have moved about 35% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 29/100 — a moderate mark against it.
Growth ranks 89/100 — a strong point in its favour. Income ranks 81/100 — a strong point in its favour. Momentum ranks 63/100 — a moderate point in its favour.
Balance-sheet strength ranks 29/100 — a moderate mark against it. Quality ranks 44/100 — a slight mark against it.
What the company does Amcor plc designs and manufactures flexible and rigid packaging solutions for nutrition, health, beauty, and wellness categories worldwide. Its products include bottles, films, trays, tubes, and closures sold through a direct sales force. The company serves customers across Europe, North America, Latin America, and Asia Pacific.
Key financials Amcor’s gross margin is 20.0% and operating margin 9.7%, with net margin at 4.7%. Revenue grew 56.6% and EPS 46.7%. ROE is 9.4% and ROA 3.6%. Debt/Equity stands at 1.28 and net debt/EBITDA at 3.97. Dividend yield is 5.7% with a payout ratio of 80.2%.
Stock health Sideravia scores Amcor Weak quality (44.0) but strong growth (88.9) and income (81.3). Momentum is mixed: +21.63% over 3 months, -3.11% over 6 months. RSI(14) is 48.00, indicating neutral momentum. Piotroski F-Score is 7/9.
Price vs fair value The stock trades at a discount of 8.80% versus the analyst mean target of 49.93. - Pharmaceutical packaging market projected to grow from $188.4B (2026) to $436.5B by 2036, highlighting Amcor’s long-term growth potential (Pharmaceutical Packaging Market Report 2026-2036). - Forward P/E of 11.53 and PEG of 0.16 suggest attractive valuation relative to earnings growth. - Dividend yield of 5.7% supports income-focused investor interest.
Looking forward Forward P/E of 11.53 and EV/EBITDA of 10.38 indicate the market is pricing in moderate growth expectations. Analysts’ mean target implies 8.80% upside from the current price. Growth and income pillars remain strong, offset by weak quality metrics.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.